- Home
- EVRG vs RPRX Comparison
EVRG vs RPRX Comparison
Compare EVRG & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EVRG | RPRX |
|---|---|---|
| Founded | 2017 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.9B | 16.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | EVRG | RPRX |
|---|---|---|
| Price | $74.52 | $39.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 3 |
| Target Price | ★ $78.35 | $46.00 |
| AVG Volume (30 Days) | 2.1M | ★ 4.4M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | ★ 3.72% | 2.23% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.66 | 1.75 |
| Revenue | ★ $5,878,800,000.00 | $2,349,844,000.00 |
| Revenue This Year | $5.19 | $36.16 |
| Revenue Next Year | $3.76 | $2.04 |
| P/E Ratio | ★ $20.44 | $22.56 |
| Revenue Growth | 1.75 | ★ 3.70 |
| 52 Week Low | $59.67 | $24.05 |
| 52 Week High | $79.32 | $41.24 |
Technical Indicators
Market Signals| Indicator | EVRG | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.23 | 59.91 |
| Support Level | $74.90 | $39.24 |
| Resistance Level | $77.63 | $40.50 |
| Average True Range (ATR) | 1.13 | 0.90 |
| MACD | -0.23 | -0.03 |
| Stochastic Oscillator | 13.30 | 83.23 |
Price Performance
Historical ComparisonAbout EVRG Evergy Inc.
Evergy is a regulated electric utility serving eastern Kansas and western Missouri. Major operating subsidiaries include Evergy Metro, Evergy Kansas Central, Evergy Missouri West, and Evergy Transmission Co. The utility has a combined rate base of approximately $20 billion, about half in Kansas and the rest split between Missouri and federal jurisdiction. Evergy is one of the largest wind energy suppliers in the US.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.